Acquired mutations associated with ibrutinib resistance in Waldenström macroglobulinemia

Ibrutinib produces high response rates and durable remissions in Waldenström macroglobulinemia (WM) that are impacted by MYD88 and CXCR4(WHIM) mutations. Disease progression can develop on ibrutinib, although the molecular basis remains to be clarified. We sequenced sorted CD19(+) lymphoplasmacytic...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Blood
Main Authors: Xu, Lian, Tsakmaklis, Nicholas, Yang, Guang, Chen, Jiaji G., Liu, Xia, Demos, Maria, Kofides, Amanda, Patterson, Christopher J., Meid, Kirsten, Gustine, Joshua, Dubeau, Toni, Palomba, M. Lia, Advani, Ranjana, Castillo, Jorge J., Furman, Richard R., Hunter, Zachary R., Treon, Steven P.
Formato: Artigo
Idioma:Inglês
Publicado em: American Society of Hematology 2017
Assuntos:
Lymphoid Neoplasia
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7484977/
https://ncbi.nlm.nih.gov/pubmed/28235842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2017-01-761726
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados